For the year ending 2025-12-31, RCUS had $72M increase in cash & cash equivalents over the period. -$484M in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Total revenues | 247 |
| Late-stage development programs | 274 |
| Early-stage development and preclinical programs | 141 |
| Compensation and personnel costs | 245 |
| Depreciation and amortization | 10 |
| Impairment of long-lived assets | 0 |
| Interest income, net | -33 |
| Income tax expense | 0 |
| Other segment items | 90 |
| Partnership reimbursements | -127 |
| Net loss | -353 |
| Stock-based compensation expense | 60 |
| Depreciation and amortization | 10 |
| Noncash lease expense | 7 |
| Impairment on right-of use assets | 0 |
| Amortization of discounts on marketable securities | 13 |
| Other items, net | 1 |
| Receivable from collaboration partners (6, 14 and 19 from a related party) | -9 |
| Other assets (, 6 and (4) from a related party) | -5 |
| Accounts payable (24, , and to a related party) | 24 |
| Deferred revenue ((240), (56) and (77) to a related party) | -240 |
| Other liabilities | 8 |
| Net cash used in operating activities | -482 |
| Purchases of marketable securities | 1,076 |
| Proceeds from maturities of marketable securities | 1,073 |
| Proceeds from sales of marketable securities | 71 |
| Purchases of property and equipment | 2 |
| Net cash provided by (used in) investing activities | 66 |
| Proceeds from issuance of common stock (14, 228 and 20 from a related party), net | 429 |
| Proceeds from debt issuances, net | 49 |
| Proceeds from issuance of common stock pursuant to equity award plans | 10 |
| Payments of employee taxes related to net settlement of equity awards | 0 |
| Net cash provided by financing activities | 488 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 72 |
| Cash, cash equivalents and restricted cash at beginning of period | 153 |
| Cash, cash equivalents and restricted cash at end of period | 225 |
Arcus Biosciences, Inc. (RCUS)
Arcus Biosciences, Inc. (RCUS)